Skip to main
  1. Stocks
  2. Medpace Holdings
  3. Forecast
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is supported by a strong late-stage CRO demand backdrop, with record 3Q net new business awards of $873 million, LTM awards up 23.9% year over year, and management expecting gross and net bookings to keep improving. The company’s win rates and RFP activity are strengthening, aided by more normalized pricing, faster customer decision timelines, and improving biotech funding, while cancellations remain within the normal 3-5% range and are driven more by product failures and reprioritization than funding pressure. Consensus still implies about 5% revenue growth and 4.5% EBITDA growth, and the $20 million Cincinnati expansion cost should later support operating leverage as the facility ramps.

Bears say

Medpace Holdings is exposed to a cyclical and policy-sensitive CRO market where government reform, macro weakness, and biotech funding constraints can reduce demand for outsourced trials and trigger elevated cancellations, particularly among smaller, pre-revenue customers. Although its $28 billion addressable market and high exposure to emerging biopharma have supported outsized growth versus peers, that same mix raises volatility, and the company’s recent improvement in bookings does not eliminate risk. Management’s rising customer concentration, with the top 5 customer revenue share estimated at 33% in 2Q and tied to a small number of large metabolic programs, creates a meaningful revenue overhang if those trials roll off.

Medpace Holdings (MEDP) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Medpace Holdings (MEDP) Analyst Forecast & Price Prediction

Get the latest Medpace Holdings (MEDP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Medpace Holdings (MEDP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 10 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $636.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $636.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Medpace Holdings (MEDP) Analyst Forecast & Price Prediction

Get the latest Medpace Holdings (MEDP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Medpace Holdings (MEDP)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MEDP stock data and trends